TB006 for Alzheimer’s: What We Know So Far About This Galectin-3 Therapy

Most people searching for new Alzheimer’s disease (AD) treatments are looking for something that could meaningfully change day-to-day function: memory, independence, communication, and quality of life. That’s why TB006, an investigational Alzheimer’s therapy, has become a topic of growing interest based on early signals reported in some patients.

We recently attended a medical conference where TB006 was one of the most discussed therapies in the Alzheimer’s space. It stood out because it challenges the “single-target” approach that has dominated AD for years and instead focuses on a pathway tied to both neuroinflammation and toxic protein aggregation.

TB006 is still in clinical development and is not FDA-approved. Today, access has largely come through clinical trials and an FDA-authorized Expanded Access (compassionate use) pathway for certain patients who meet criteria.

What Is TB006 and How Does It Work?

TB006 is an investigational monoclonal antibody that targets galectin-3 and is being studied as a potential new treatment for Alzheimer’s disease.

Most Alzheimer’s drugs focus on managing symptoms or addressing plaques after damage has already occurred. TB006 takes a different approach by targeting galectin-3, a protein tied to chronic inflammation in the brain and the biological environment that allows plaque formation to continue. That distinction matters because it reflects a broader shift in how Alzheimer’s disease is being understood and studied.

At this stage, it is administered as a monthly IV therapy.

While it’s primarily being researched for Alzheimer’s disease, there’s growing interest in Parkinson’s disease as well. What makes TB006 different isn’t how it’s given. It’s what it targets.

What’s Galectin-3?

Galectin-3 is a protein that shows up in much higher levels in the brains of people with Alzheimer’s disease. Over time, researchers have realized galectin-3 does more than just hang around in damaged brain tissue.

Galectin-3 appears to:

• Help amyloid proteins clump together
• Act like scaffolding that supports plaque buildup
• Fuel ongoing inflammation in the brain
• Keep the disease process “turned on”

In basic terms, galectin-3 helps create the environment where Alzheimer’s disease can continue to progress.

What Is TB006 Trying to Do?

TB006 is designed to bind to galectin-3 and block its ability to do those things. By targeting galectin-3 directly, the goal is to:

• Slow down amyloid aggregation
• Disrupt plaque formation
• Reduce inflammatory signaling
• Support healthier communication between brain cells

Most Alzheimer’s disease drugs focus on cleaning up plaques after the damage is done. TB006 is trying to interfere earlier in the process, at the level of inflammation and protein behavior. That shift is why researchers are paying attention.

What the Research Shows So Far

At the conference, the number that kept coming up was this: roughly 47% of patients receiving the IV reported significant improvement. That is not a small claim in Alzheimer’s research, and it is why the chatter around TB006 is so loud right now.

They also showed before-and-after examples that were hard to ignore. One patient went from struggling with basic movement to moving much more freely after treatment. That kind of change gets attention. However, it is also not the same thing as long-term clinical proof.

Two other important takeaways came up in the discussion:

• Response time varies. Some people appear to notice changes after one infusion. Others may need three to six months before anything shifts.
  
• Not everyone responds. There is also a genetic factor being discussed, where one specific SNP may predict non-response.
  

The signal is exciting. There are limitations though. And the next steps depend on what the trials prove.

What TB006 Treatment Looks Like

At the moment, TB006 is expensive (3K per IV), limited in access, investigation, and not part of standard Alzheimer’s care. 

Right now, TB006 is studied as:

• An IV infusion
• About one hour per session
• Given every 28 days
• Intended as ongoing treatment, not a one-time fix

Is TB006 Being Studied for Parkinson’s Disease?

Yes, TB006 is also being studied for Parkinson’s disease. Galectin-3 is involved in inflammation and protein aggregation beyond Alzheimer’s disease. In Parkinson’s disease, similar processes occur with different proteins, like alpha-synuclein. 

Because galectin-3 plays a role in how these proteins clump and how inflammation stays active, researchers are exploring whether targeting it could help across multiple neurodegenerative conditions.

Parkinson’s is an area of interest and trials are underway. 

TB006 and the Future of Alzheimer’s Treatment

TB006 reinforces that Alzheimer’s disease is not just about plaques. It’s about inflammation, immune signaling, and the biological environment that allows damage to continue.

By targeting galectin-3, TB006 helps move the conversation forward, highlighting that Alzheimer’s is more complex than amyloid plaque alone. This IV-based treatment supports the idea that effective Alzheimer’s plaque removal therapy may need to address inflammation and aggregation together, not separately.

From our perspective, that’s progress. This is how better treatments are built. Not overnight and not perfectly, but by slowly improving how we understand the disease itself.

Questions Our Patients Are Asking About TB006

What Is TB006 Used For?

TB006 is an investigational therapy being studied primarily as an Alzheimer’s disease medication. It targets galectin-3, a protein involved in inflammation and plaque formation.

Is TB006 FDA Approved?

No. TB006 is still in clinical trials and is not yet FDA approved.

How Is TB006 Different From Other Alzheimer’s Disease Drugs?

Most Alzheimer’s disease drugs focus on symptoms or plaque removal alone. TB006 targets galectin-3, which plays a role in both inflammation and plaque development.

Does TB006 Remove Alzheimer’s Plaques?

TB006 is designed to interfere with plaque formation and may support plaque reduction, but research is ongoing and results are still being evaluated.

When Will TB006 Become Widely Available?

That depends on the outcome of TB006 clinical trials and the FDA approval process. Realistically, this could take several years.